Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.60 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.46 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1332322 | 0.81 | PIK3CA (0.53) | CNR2KDM4EMAPTALDH1A1LMNA | |
| SCHEMBL3828767 | 0.80 | ALOX5AP (0.50) | CNR2KDM4EALOX5AP | |
| SCHEMBL29739351 | 0.78 | UBE2T (0.54) | CNR2CNR1KDM4EUBE2TMAPT | |
| SCHEMBL2744803 | 0.78 | UBE2T (0.54) | CNR2CNR1KDM4EUBE2TMAPT | |
| SCHEMBL922771 | 0.78 | UBE2T (0.54) | CNR2CNR1KDM4EUBE2TMAPT | |
| Hydrochloric Acid SCHEMBL1984542 | 0.77 | UBE2T (0.53) | CNR2CNR1KDM4EUBE2TMAPT | |
| SCHEMBL29884840 | 0.76 | CNR2 (0.57) | CNR2KDM4EMAPTALDH1A1 | |
| SCHEMBL21223162 | 0.76 | CNR2 (0.54) | CNR2CNR1KDM4EUBE2TPIK3CA | |
| SCHEMBL241019 | 0.76 | UBE2T (0.56) | CNR2CNR1KDM4EUBE2TMAPT | |
| SCHEMBL29377723 | 0.76 | UBE2T (0.56) | CNR2CNR1KDM4EUBE2TMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513242-B2 | Pyrimidine compounds and methods of making and using same | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110281873-A1 | Pyrimidine Compounds and Methods of Making and Using Same | CYSTIC FIBROSIS FOUNDATION | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281873-A1 | Pyrimidine Compounds and Methods of Making and Using Same | CFTR, GPR17, TYMS | CNR2 836/4885CNR1 1055/4885KDM4E 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.